Tsingtao Brewery Company Limited (Stock Code: 168) has entered into multiple framework agreements with Tsingtao Brewery Group and its affiliated entities for the year 2026. These agreements encompass service provisions and leasing arrangements, product purchases and sales, trademark licensing, supply chain services, and an overseas exclusive distribution agreement.
Under the new Comprehensive Services Framework Agreement, effective from 1 January 2026 to 31 December 2026, the Group will provide product development, examination, information network, human resources, as well as property management services, and will lease houses and facilities as needed. The annual transaction cap is estimated at RMB55.6925 million.
An Entrusted Production, Product Purchase and Sale, and Asset Leasing Framework Agreement was also entered into. It covers Qingdao Beverage Group’s entrusted production of certain beverage products, procurement of brewery products, retail distribution of packaged beverages, and leasing of factory premises. The annual cap for these transactions is estimated at RMB41.50 million.
The Trademark License Agreement allows the use of the “TSINGTAO” and other registered trademarks under the Group by Youjia Health and related entities in their business operations. The license fee corresponds to 1.2% of net sales income for the licensed products, with a 2026 cap of RMB2.20 million.
Under the Supply Chain Services Framework Agreement, Zhilian Shunda Group will provide transportation, logistics, warehousing, equipment leasing, and value-added services to the Group. It will also lease idle warehouses and purchase beer products from the Group, among other import–export activities. The cap is estimated at RMB1,239.00 million for 2026.
In addition, the Overseas Exclusive Agency Distribution Framework Agreement, originally effective from 1 July 2025 to 31 December 2025, has been extended through 2026. Tsingtao Brewery International will remain the exclusive distributor of Qingdao Beverage Group’s products overseas, with an annual cap estimated at RMB4.5 million.
All relevant percentage ratios under these agreements exceed 0.1% but remain below 5%. The transactions are thus subject to reporting, annual review, and announcement requirements under the Listing Rules, while independent shareholders’ approval is not required.
Comments